Luciano J. Costa, MD, PhD

Articles

Relapsed/Refractory Multiple Myeloma: Future Directions in Care

June 16th 2022

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.

Moving Bispecific and CAR T-Cell Therapies to Earlier Lines of Therapy in MM

June 16th 2022

Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.

Multiple Myeloma: Sequencing Novel Bispecific and CAR T-Cell Therapies

June 9th 2022

In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.

MonumenTAL-1: Talquetamab in Relapsed or Refractory Multiple Myeloma

June 9th 2022

Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.

Patient Scenario 2: A 57-Year-Old With Heavily Pretreated MM

June 2nd 2022

Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.

MajesTEC-1: Teclistamab in Relapsed or Refractory Multiple Myeloma

June 2nd 2022

Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.

Triple-Class Refractory MM: Factors in Selecting Optimal Therapy

May 26th 2022

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

Patient Scenario 1: A 66-Year-Old With Triple-Class Refractory MM

May 26th 2022

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

Dr. Costa on Developing Later-Line Therapies for the Frontline Setting in Multiple Myeloma

April 28th 2021

Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.

Dr. Costa on the Evolving Treatment Paradigm in Newly Diagnosed Multiple Myeloma

April 14th 2021

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma

September 14th 2020

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma

September 9th 2020

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma

August 6th 2020

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Dr. Costa on the Design of a First-in-Human Study With CC-93269 in R/R Myeloma

July 13th 2020

Luciano J. Costa, MD, PhD, discusses the design of a phase 1 first-in-human study with CC-93269 in relapsed/refractory multiple myeloma.

Dr. Costa on CC-93269 in Relapsed/Refractory Multiple Myeloma

June 29th 2020

Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.

Dr. Costa on Safety of CC-93269 in Relapsed/Refractory Myeloma

June 12th 2020

Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.

Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma

June 3rd 2018

Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.